Erythropoietic agents in routine clinical practice: a retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in anaemia patients with cancer

被引：0
|
作者：
Pujade-Lauraine, Eric [1 ]
Richard, Alain J. [2 ]
Sapede, Claudine [3 ]
机构：
[1] CHU, Hotel Dieu, Serv Oncol, Paris, France
[2] GECEM SA, Paris, France
[3] F Hoffmann La Roche & Cie AG, PBSE, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [31] Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
    Rosti, Giovanni
    Petrini, Mario
    Bosi, Alberto
    Galieni, Piero
    Bernardi, Daniele
    Giglio, Gianfranco
    Dorotea, Laura
    Falini, Brunangelo
    Scelzi, Elvira
    Veltri, Enzo
    Castelli, Roberto
    Longagnani, Chiara
    Raggi, Tommaso
    Simonetti, Federico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (01) : 22 - 32
  • [32] CONVERSION FROM EPOETIN ALFA TO DARBEPOETIN ALFA IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE: FRENCH MONOCENTRE OBSERVATIONAL STUDY
    Binaut, R.
    Bacri, J. L.
    Fleury, D.
    Maisonneuve, N.
    Labatut, D.
    Lemaitre, V
    Medeghri, Z.
    Bir, G.
    Lanier, J.
    VALUE IN HEALTH, 2012, 15 (07) : A458 - A459
  • [33] Propensity score matched evaluation of epoetin alfa and darbepoetin alfa utilization in patients with cancer receiving chemotherapy.
    Bailey, R. A.
    Tunceli, O.
    Singer, J.
    Stephenson, J. J.
    Senbetta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Darbepoetin alfa is cost effective compared to epoetin alfa for treatment of anemia in cancer patients receiving chemotherapy.
    Glaspy, JA
    Tchekmedyian, NS
    Gupta, S
    BLOOD, 2002, 100 (11) : 874A - 875A
  • [35] Epoetin alfa: basic biology and clinical utility in cancer patients
    Littlewood, Timothy
    Collins, Graham
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (06) : 947 - 956
  • [36] Clinical benefits and risks associated with darbepoetin alfa and epoetin alfa treatment in patients with lung cancer and chemotherapy-induced anemia.
    Tiotiu, Angelica
    Clerc-Urmes, Isabelle
    Chabot, Francois
    Martinet, Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Dutch observational study on anaemia management with epoetin alfa in daily oncology practice - interim analysis results on lung cancer patients
    Lunde, Ragnar
    Strankinga, Wim
    van den Berg, Paul
    Bunnik, Rene
    Schlosser, Noel
    van Rens, Marcel
    Aerts, Joachim
    Brok, Ronald
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S432 - S432
  • [38] Update on clinical practice guideline on the use of epoetin and darbepoetin in adult patients with cancer
    Clayton, Julie
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2013, 2 (02): : 97 - 98
  • [39] Comparison of epoetin alfa (EPO) and darbepoetin alfa (DARB) utilization in cancer chemotherapy patients treated in a hospital outpatient setting
    Vekeman, F.
    LaFeuille, M.
    Bailey, R.
    Piech, C. Tak
    McKenzie, R. S.
    Lefebvre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
    Samper Ots, Pilar Ma
    Lopez Carrizosa, Concepcion
    Rodriguez Perez, Aurora
    Saez Garrido, Juan de Dios
    Delgado Perez, Jose Ma
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 393 - 399
12345